Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.
Hayder Saeed, MD
Advertisement
Articles by Hayder Saeed, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
4
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
5